Literature DB >> 24388212

Multifarious determinants of cytokine receptor signaling specificity.

Ignacio Moraga1, Jamie Spangler1, Juan L Mendoza1, K Christopher Garcia2.   

Abstract

Cytokines play crucial roles in regulating immune homeostasis. Two important characteristics of most cytokines are pleiotropy, defined as the ability of one cytokine to exhibit diverse functionalities, and redundancy, defined as the ability of multiple cytokines to exert overlapping activities. Identifying the determinants for unique cellular responses to cytokines in the face of shared receptor usage, pleiotropy, and redundancy will be essential in order to harness the potential of cytokines as therapeutics. Here, we discuss the biophysical (ligand-receptor geometry and affinity) and cellular (receptor trafficking and intracellular abundance of signaling molecules) parameters that contribute to the specificity of cytokine bioactivities. Whereas the role of extracellular ternary complex geometry in cytokine-induced signaling is still not completely elucidated, cytokine-receptor affinity is known to impact signaling through modulation of the stability and kinetics of ternary complex formation. Receptor trafficking also plays an important and likely underappreciated role in the diversification of cytokine bioactivities but it has been challenging to experimentally probe trafficking effects. We also review recent efforts to quantify levels of intracellular signaling components, as second messenger abundance can affect cytokine-induced bioactivities both quantitatively and qualitatively. We conclude by discussing the application of protein engineering to develop therapeutically relevant cytokines with reduced pleiotropy and redirected biological functionalities.
© 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cytokine engineering; Cytokine signaling; Cytokine structure; Functional specificity; Interleukin; Ligand–receptor affinity; Receptor trafficking

Mesh:

Substances:

Year:  2014        PMID: 24388212      PMCID: PMC4449261          DOI: 10.1016/B978-0-12-800100-4.00001-5

Source DB:  PubMed          Journal:  Adv Immunol        ISSN: 0065-2776            Impact factor:   3.543


  190 in total

1.  Rational design of potent antagonists to the human growth hormone receptor.

Authors:  G Fuh; B C Cunningham; R Fukunaga; S Nagata; D V Goeddel; J A Wells
Journal:  Science       Date:  1992-06-19       Impact factor: 47.728

2.  IL-4 receptor alpha is an important modulator of IL-4 and IL-13 receptor binding: implications for the development of therapeutic targets.

Authors:  Allison-Lynn Andrews; John W Holloway; Stephen T Holgate; Donna E Davies
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

3.  Structure of IL-22 bound to its high-affinity IL-22R1 chain.

Authors:  Brandi C Jones; Naomi J Logsdon; Mark R Walter
Journal:  Structure       Date:  2008-07-03       Impact factor: 5.006

4.  The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif.

Authors:  S N Constantinescu; L J Huang; H Nam; H F Lodish
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

5.  Stat6 is necessary and sufficient for IL-4's role in Th2 differentiation and cell expansion.

Authors:  J Zhu; L Guo; C J Watson; J Hu-Li; W E Paul
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

6.  Mechanism-based design of prolactin receptor antagonists.

Authors:  G Fuh; P Colosi; W I Wood; J A Wells
Journal:  J Biol Chem       Date:  1993-03-15       Impact factor: 5.157

7.  Cytoskeletal association of human alpha-interferon-receptor complexes in interferon-sensitive and -resistant lymphoblastoid cells.

Authors:  L M Pfeffer; N Stebbing; D B Donner
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

8.  Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130.

Authors:  Martin J Boulanger; Alexander J Bankovich; Tanja Kortemme; David Baker; K Christopher Garcia
Journal:  Mol Cell       Date:  2003-09       Impact factor: 17.970

9.  A diverse range of gene products are effectors of the type I interferon antiviral response.

Authors:  John W Schoggins; Sam J Wilson; Maryline Panis; Mary Y Murphy; Christopher T Jones; Paul Bieniasz; Charles M Rice
Journal:  Nature       Date:  2011-04-10       Impact factor: 49.962

10.  Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines.

Authors:  Ilkka S Junttila; Remi J Creusot; Ignacio Moraga; Darren L Bates; Michael T Wong; Michael N Alonso; Megan M Suhoski; Patrick Lupardus; Martin Meier-Schellersheim; Edgar G Engleman; Paul J Utz; C Garrison Fathman; William E Paul; K Christopher Garcia
Journal:  Nat Chem Biol       Date:  2012-10-28       Impact factor: 15.040

View more
  24 in total

1.  Absolute Ligand Discrimination by Dimeric Signaling Receptors.

Authors:  Sepehr Fathi; Chitra R Nayak; Jordan J Feld; Anton G Zilman
Journal:  Biophys J       Date:  2016-09-06       Impact factor: 4.033

2.  Topological control of cytokine receptor signaling induces differential effects in hematopoiesis.

Authors:  Kritika Mohan; George Ueda; Ah Ram Kim; Kevin M Jude; Jorge A Fallas; Yu Guo; Maximillian Hafer; Yi Miao; Robert A Saxton; Jacob Piehler; Vijay G Sankaran; David Baker; K Christopher Garcia
Journal:  Science       Date:  2019-05-23       Impact factor: 47.728

3.  Decoupling the Functional Pleiotropy of Stem Cell Factor by Tuning c-Kit Signaling.

Authors:  Chia Chi M Ho; Akanksha Chhabra; Philipp Starkl; Peter-John Schnorr; Stephan Wilmes; Ignacio Moraga; Hye-Sook Kwon; Nicolas Gaudenzio; Riccardo Sibilano; Tom S Wehrman; Milica Gakovic; Jonathan T Sockolosky; Matthew R Tiffany; Aaron M Ring; Jacob Piehler; Irving L Weissman; Stephen J Galli; Judith A Shizuru; K Christopher Garcia
Journal:  Cell       Date:  2017-03-09       Impact factor: 41.582

4.  Using Immune Marker Panels to Evaluate the Role of Inflammation in Cancer: Summary of an NCI-sponsored Workshop.

Authors:  Danielle M Carrick; Anil K Chaturvedi; Meredith S Shiels; Rao L Divi; Kelly K Filipski; Elizabeth F Hebert; Mukesh Verma; Allan Hildesheim
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-06-24       Impact factor: 4.254

5.  Tumor Necrosis Factor α Receptor Type 1 Activation in the Hypothalamic Paraventricular Nucleus Contributes to Glutamate Signaling and Angiotensin II-Dependent Hypertension.

Authors:  Clara Woods; Jose Marques-Lopes; Natalina H Contoreggi; Teresa A Milner; Virginia M Pickel; Gang Wang; Michael J Glass
Journal:  J Neurosci       Date:  2020-12-10       Impact factor: 6.167

6.  Hub Gene Screening and Prognostic Modeling of Lung Cancer: An Integrated Bioinformatics Study.

Authors:  Henan Bai; Xiangdong Huang
Journal:  Comput Math Methods Med       Date:  2022-07-05       Impact factor: 2.809

7.  Type I Interferon Signaling Is Decoupled from Specific Receptor Orientation through Lenient Requirements of the Transmembrane Domain.

Authors:  Nanaocha Sharma; Geeta Longjam; Gideon Schreiber
Journal:  J Biol Chem       Date:  2015-12-17       Impact factor: 5.157

8.  Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy.

Authors:  Jamie B Spangler; Eleonora Trotta; Jakub Tomala; Ariana Peck; Tracy A Young; Christina S Savvides; Stephanie Silveria; Petra Votavova; Joshua Salafsky; Vijay S Pande; Marek Kovar; Jeffrey A Bluestone; K Christopher Garcia
Journal:  J Immunol       Date:  2018-08-13       Impact factor: 5.422

9.  Instructive roles for cytokine-receptor binding parameters in determining signaling and functional potency.

Authors:  Ignacio Moraga; David Richter; Stephan Wilmes; Hauke Winkelmann; Kevin Jude; Christoph Thomas; Megan M Suhoski; Edgar G Engleman; Jacob Piehler; K Christopher Garcia
Journal:  Sci Signal       Date:  2015-11-10       Impact factor: 8.192

Review 10.  Insights into cytokine-receptor interactions from cytokine engineering.

Authors:  Jamie B Spangler; Ignacio Moraga; Juan L Mendoza; K Christopher Garcia
Journal:  Annu Rev Immunol       Date:  2014-12-10       Impact factor: 28.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.